Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant sintilimab + ipilimumab N01 + chemotherapy for resectable cN1/N2 driver-negative NSCLC
ChiCTR2600134141Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and ipilimumab in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Pathological complete response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sintilimabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600134141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134141.